Last updated: 2026-09-09 05:49:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lexeo Therapeutics, Inc. (LXEO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.77, with a market capitalization of $401.21M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.99 to $10.99. This page covers its latest market performance, valuation, price trends and company information.
$401.21M | |
$4.82 | |
$22.33 | |
$1.45 | |
$4.89 | |
272.15K | |
922.58K | |
-- | |
$10.99 | |
$3.99 | |
-- | |
-- |
Lexeo Therapeutics, Inc. (LXEO) last closed at $4.89 as of 2026-09-08 23:31:00, unchanged from the previous close of $4.89.
During the latest regular trading session, LXEO traded between $1.45 and $22.33, with a volume of 272.15K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Lexeo Therapeutics, Inc. (LXEO) moved from $4.99 to $4.77, representing a decline of 4.39% ($0.22).
The stock traded between $4.56 and $5.28 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 534.28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.2%
LXEO is currently trading at $4.77, placing it 11.2% of the way from its 52-week low of $3.99 to its 52-week high of $10.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 59 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lexeo Therapeutics, Inc. (LXEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.